Selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 for patients with metabolic syndrome: is the target liver, fat, or both?
Stewart
Paul M
PM
Department of Endocrinology, University of Birmingham and University Hospital Birmingham National Health Service Foundation Trust, Birmingham, UK. p.m.stewart@bham.ac.uk
Tomlinson
Jeremy W
JW
D043205:11-beta-Hydroxysteroid Dehydrogenase Type 1 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000273:Adipose Tissue / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage / Q000627:therapeutic use; D050152:Intra-Abdominal Fat / Q000378:metabolism; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D024821:Metabolic Syndrome / Q000188:drug therapy* / Q000201:enzymology / Q000378:metabolism; D013152:Splanchnic Circulation / Q000187:drug effects
D043205:11-beta-Hydroxysteroid Dehydrogenase Type 1; D006854:Hydrocortisone